PharmaMar is a Spain-based biopharmaceutical company that specializes in the discovery and development of novel oncology therapies derived from marine organisms. Founded in 1986 as part of Grupo Zeltia, the company has pioneered the use of compounds extracted from deep-sea organisms to create synthetic analogs aimed at treating various forms of cancer. Its core expertise lies in marine biotechnology, medicinal chemistry and oncology-focused clinical development.
The company’s flagship product is Yondelis (trabectedin), an antitumor agent approved in the European Union for the treatment of soft tissue sarcoma and relapsed platinum-sensitive ovarian cancer. In collaboration with international partners, PharmaMar has also advanced lurbinectedin (Zepzelca) through clinical trials, securing FDA approval in the United States for the treatment of metastatic small cell lung cancer. Additional pipeline candidates include plitidepsin (Aplidin), currently under review for hematological malignancies and other oncology indications.
Headquartered in Madrid, PharmaMar maintains research facilities in Spain and operates through a network of licensing agreements and strategic partnerships across Europe, North America and Asia Pacific. The company’s subsidiaries, such as Genomica (molecular diagnostics) and Sylentis (RNA interference therapeutics), extend its capabilities into precision medicine and genomic technologies, reinforcing its integrated approach to cancer research and patient care.
Under the leadership of President and CEO José María Fernández Sousa-Faro, PharmaMar continues to expand its global footprint by advancing late-stage clinical programs and negotiating regional commercialization deals. The company’s ongoing commitment to marine-based drug discovery positions it as a distinctive player in the oncology landscape, with a focus on unmet medical needs and innovative therapeutic solutions.
AI Generated. May Contain Errors.
